Selectively altering microbiota for immune modulation

Patent metadata

Field	Value
Publication number	US-2018303934-A1
Application number	US-201816028311-A
Country	US
Kind code	A1
Filing date	Jul 5, 2018
Priority date	Jun 5, 2016
Publication date	Oct 25, 2018
Grant date	—

Abstract

The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

First claim

1 . A method for modulating a therapy of a disease or condition in a human or animal patient, the method comprises selective killing or reducing growth of a target bacterial or archaeal sub-population of a microbiota using a guided nuclease, thereby increasing the relative proportion of a sub-population of gram negative bacteria in the microbiota, wherein the therapy comprises administration of an effective amount of an immune checkpoint inhibitor to the patient, and wherein the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor.

2 . The method of claim 1 , wherein the guided nuclease is a Cas, TALEN, meganuclease or zinc finger nuclease.

3 . The method of claim 2 , wherein the microbiota comprises a mixed population of human gut microbiota bacteria of different species, and wherein the selective killing comprises selectively killing cells of one or more of the different species and sparing cells of the other species.

4 . The method of claim 1 , wherein the sub-population of gram negative bacteria comprise Akkermansia.

5 . The method of claim 1 , wherein the immune checkpoint inhibitor is an antibody.

6 . The method of claim 5 , wherein the immune checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, durvalumab, or atezolizumab.

7 . The method of claim 1 , wherein the microbiota is gut microbiota.

8 . The method of claim 1 , wherein the sub-population of gram negative bacteria comprise Akkermansia muciniphila.

9 . The method of claim 1 , wherein the disease is cancer.

10 . The method of claim 9 , wherein the cancer is melanoma, non-small-cell lung cancer (NSCLC), or renal cell carcinoma (RCC).

11 . The method of claim 1 , wherein the sub-population of gram negative bacteria comprise Faecalibacterium.

12 . The method of claim 1 , wherein the sub-population of gram negative bacteria comprise Faecalibacterium prausnitzii.

13 . The method of claim 1 , wherein the target sub-population comprises Bacteroidetes.

14 . The method of claim 1 , wherein the method comprises:
a. contacting the microbiota with an engineered nucleic acid sequence for producing a host modifying (HM) crRNA, and b. producing the HM-crRNA in a host cell of the target sub-population, wherein the HM-crRNA is operable with a Cas nuclease in the host cell to form a HM-CRISPR/Cas system, and wherein the HM-crRNA comprises a sequence that is capable of hybridizing to a target sequence of the host cell to guide the Cas nuclease to the target sequence in the host cell, whereby the target sequence is modified by the HM-CRISPR/Cas system and the host cell is killed or growth of the target sub-population is reduced.

15 . The method of claim 14 , wherein the Cas nuclease is endogenous to the host cell.

16 . The method of claim 14 , wherein the Cas nuclease is a Type II Cas.

17 . The method of claim 16 , wherein the HM-CRISPR/Cas system comprises an endogenous tracrRNA of the host cell.

18 . The method of claim 16 , wherein the HM-CRISPR/Cas system comprises a tracrRNA, and wherein the tracrRNA is encoded by an engineered nucleic acid.

19 . The method of claim 14 , wherein the sub-population of gram negative bacteria comprise Akkermansia.

20 . The method of claim 14 , wherein the sub-population of gram negative bacteria comprise Faecalibacterium.

Assignees

• Snipr Tech Ltd

Inventors

• Clube Jasper
• Sommer Morten
• Grøndahl Christian
• Vazquez-Uribe Ruben
• Van Der Helm Eric

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K31/7105 Primary

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

• A61P35/00

  Antineoplastic agents · CPC title